Synergistic combinations of the dual enkephalinase inhibitor PL265 given orally with various analgesic compounds acting on different targets, in a murine model of cancer-induced bone pain

Protecting endogenous enkephalins from their degradation using dual enkephalinase inhibitors (DENKIs) has been shown to elicit antinociceptive responses in various rodent pain models. Antinociceptive effects of the new DENKI PL265 were evaluated in mice inoculated with B16-F10 melanoma cells into the tibia. The oral administration of PL265 (12.5-100 mg/kg) reduced thermal hyperalgesia and mechanical allodynia. The antihyperalgesic effects were antagonized by earlier administration of naloxone-methiodide or cyprodime but not by naltrindole or nor-binaltorphimine, confirming that only peripheral mu-opioid receptors were involved. Several antinociceptive drugs, acting through different pathways, like gabapentin, a ligand of calcium channel sub-unit 2, a P2X3 receptor antagonist (A-317491), a CB1 receptor agonist (ACEA), two CB2 receptor agonists (AM1241 and JWH-133), an inhibitor of the degradation of endogenous cannabinoids (URB937) and a Nav1.7 blocker (NAV26), showed antihyperalgesic effects in this model. Isobolographic analysis of the effects of their combined administration with PL265 shows a synergy, with an interaction index from 0.3 to 0.7, except for JWH133, a drug with antihyperalgesic effects unrelated to the stimulation of opioid receptors. The synergistic antihyperalgesic effects of these drug combinations may be of clinical interest, reducing required doses and thereby the side-effects of often ill-tolerated drugs.

Download Full Version

Publications - Latest posts

Discover our publications
Press & media coverage
Contact & find us

Pharmaleads SA
11, rue Watt
75013 Paris

Tel: +33 (0)1 44 06 70 00
Fax: +33 (0)1 44 06 60 99
info@pharmaleads.com

Get the access map